Overview

Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker

Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Observation has pointed out, that osteitis present in the MRI scans, predicts bone erosion and that this in accordance with the concept by underlining the importance of bone marrow involvement in arthritis [Krabben A, 2013]. Abatacept with its favourable safety profile preferentially interrupts activation of naïve T cells and perhaps makes the strongest case for exploiting co-stimulatory blockade during the earliest detectable phase of the adaptive immune response at a time when predisposition to autoimmune disease can be detected.
Phase:
Phase 4
Details
Lead Sponsor:
University of Erlangen-Nürnberg Medical School
Treatments:
Abatacept